All of the patients with LA-HR+/HER2- breast cancer would have likely benefited from extended endocrine therapy as well as adjuvant cyclin-dependent kinase 4/6 inhibitors, though it is likely that many of the patients did not receive these treatments in the given study period [35,41,42]. The gene discussed is HR; the disease is breast carcinoma.